Reviewing Developments in the World of Antibody-Drug Conjugates & Canvassing Current Perspectives on the Field

8:00 am Chairperson’s Opening Remarks

  • Puja Sapra Senior Vice President, Head R&D Biologics Engineering & Head Oncology Targeted Delivery, AstraZeneca

8:15 am Industry Leaders’ Panel Discussion

  • Puja Sapra Senior Vice President, Head R&D Biologics Engineering & Head Oncology Targeted Delivery, AstraZeneca
  • Tim Lowinger Chief Scientific & Technology Officer, Mersana Therapeutics
  • Trevor Hallam Chief Scientific Officer & President, Research, Sutro Biopharma
  • Mimi Huizinga Senior Vice President, Medical Affairs, ImmunoGen

Synopsis

  • Outlining the most exciting developments within the last 12 months
  • Exploring what the current clinical and commercialization landscape looks like
  • Sharing the biggest up and coming trends within the ADC field
  • Examining the next big challenges ADC developers will face

9:00 am Harnessing the Power of ADCs By Careful Selection of Target, Linker, Payload, Indication, & Combination Partner

Synopsis

  • Providing an overview of Seagen’s novel ADC pipeline
  • Creating best-in-class ADC opportunities through strategic pairing of target, linker, payload, and drug-antibody ratio (DAR)
  • Sharing combination strategies tailored to ADCs based on the unique mechanism of action

9:30 am Leveraging a Unique Suite of ADC Technologies to Ensure Safe Payload Delivery & Make the Right Match in ADC Design

Synopsis

  • Discussing Tubulis’ differentiated ADC technology platform enabling a broad design space to make the right match between indication, target, linker and payload
  • Taking a holistic approach to optimize ADC biophysical properties and thereby minimize target-independent toxicities
  • Tub-tag conjugation – Reviewing a biology-inspired enzymatic conjugation system

10:00 am
Speed Networking

Synopsis

This session is the ideal opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with. Use this time to get back to face-to-face interaction with many of the brightest minds working in the ADC field and establish meaningful business relationships.

12:30 pm
Lunch & Networking Supported by BSP Pharmaceuticals

3:00 pm
Afternoon Break & Technology Slam

Seeing Uniform PEGs (dPEGs) in ADCs Beyond Linkers Alone

Analyzing Approaches to Developing & Advancing Novel ADCs into the Clinic

3:45 pm Antibody Targeted Amanitin Conjugates (ATAC): A New Payload Provides New Options for Cancer Therapy

  • Andreas Pahl Chief Scientific Officer, Heidelberg Pharma Research

Synopsis

  • Discussing a new payload with a new mode of action providing new options to fight cancer
  • Understanding how the ATAC platform optimized the ADC technology for that payload
  • Reviewing HDP-101 targeting BCMA; the first ATAC which cleared IND and is now in dose escalation in myeloma patients

4:15 pm Expansion of toxSYN Platform with Best-in-Class Linker Payloads Based on Validated Topiosomerase 1 Inhibitor (Exatecap) & DNA-damaging Agent (Calicheamicin)

Synopsis

  • Demonstrating how SYNtecan E™ and SYNeamicin G™ linker-payloads show excellent in vivo efficacy and tolerability
  • Immunogenic cell-death driven by SYNtecan E™ ADCs corroborated in syngeneic mouse models
  • Discussing how a comprehensive set of linker-payloads enables matching of payload MOA to any clinical indication

4:45 pm Beyond Cytotoxic ADCs & Immunogenic Cell Death: Advancing ADCs Fully Into Immuno-oncology

  • Tim Lowinger Chief Scientific & Technology Officer, Mersana Therapeutics

Synopsis

  • Design and optimization of the Immunosynthen STING agonist ADC platform
  • Extensive characterization of the pre-clinical profile of XMT-2056, a novel, Her-2 targeted Immunosynthen ADC
  • Translational Research demonstrating the mechanism of an Immnosynthen ADC and its ability to activate the STING pathway in tumor cells and tumor-resident immune cells to deliver a “1-2 punch”

5:15 pm Pan-Tumoral Small Molecule-Drug Conjugates Targeting Fibroblasts Activation Protein in Solid Lesions

Synopsis

  • OncoFAP is a clinically validated small organic ligand targeting FAP in solid tumors
  • Discover how OncoFAP-drug conjugates selectively target tumors in vivo and release high amount of MMAE at the site of disease
  • Explore how OncoFAP-drug conjugates potently induce anti-tumor response at doses below tumor saturation both in monotherapy and in combination with immunotherapy

5:45 pm End of Scientific Program Day One

Scientific Poster Session

Synopsis

After the formal presentations have finished, the learning and networking carries on. The Scientific Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session over 50 posters will be shared covering all aspects of ADC Research and development!

Find out more.